氘代药物及其在抗肿瘤新药研发中的应用前景

Deuterated drugs and their application prospects in the development of new anti-tumor drugs

氘代药物是将药物分子上特定位点进行氘-氢原子替换所获得的药物。本文旨在帮助读者了解氘代化技术的原理、适用类型以及多纳非尼为代表的氘代抗肿瘤新药的研发情况。本文以“Deuterated”和“Deuterium”等作为关键词检索PubMed及ClinicalTrials数据库,解析氘代技术的原理和药物特点,综述近年来与抗肿瘤药物研发有关的进展。文献表明氘代设计可以改变药物特性,延长其在体内的作用时间、减少给药剂量、提高疗效并减少毒性反应;因此,多纳非尼具备明显的优势,用于治疗晚期肝细胞癌,较索拉非尼进一步延长患者的总生存期,且安全性和耐受性良好,以其为代表的氘代抗肿瘤新药的前景广阔。

Deuterated drugs are obtained by substituting deuterium and hydrogen atoms at specific sites on drug molecules.This paper aims to help readers understand the principle and applicable types of deuterization technology,as well as the research and development of deuterated anti-tumor drugs represented by donafenib.In this paper,“deuterated”and“deuterium”were used as keywords to search PubMed and ClinicalTrials databases,analyze the principle and drug characteristics of deuterium technology,and to review the progress in the research and development of anti-tumor drugs in recent years.The literature shows that deuterium design can change the drug characteristics,prolong its action time in vivo,reduce the dosage,improve the curative effect,and reduce the toxic reaction.Therefore,donafenib has obvious advantages in the treatment of advanced hepatocellular carcinoma,which further prolongs the overall survival of patients compared with sorafenib,and has good safety and tolerance.Deuterated anti-tumor drugs represented by donafenib have broad prospects.